How will aducanumab approval impact ad research?

Weiner, M.W.; Aisen, P.S.; Beckett, L.A.; Green, R.C.; Jagust, W.; Morris, J.C.; Okonkwo, O.; Perrin, R.J.; Petersen, R.C.; Rivera Mindt, M.; Saykin, A.J.; Shaw, L.M.; Toga, A.W.; Trojanowski, J.Q.; the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and

Archives

journal articles

HOW WILL ADUCANUMAB APPROVAL IMPACT AD RESEARCH?

M.W. Weiner, P.S. Aisen, L.A. Beckett, R.C. Green, W. Jagust, J.C. Morris, O. Okonkwo, R.J. Perrin, R.C. Petersen, M. Rivera Mindt, A.J. Saykin, L.M. Shaw, A.W. Toga, J.Q. Trojanowski, and the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

J Prev Alz Dis 2021;4(8):391-392

CITATION:
M.W. Weiner ; P.S. Aisen ; L.A. Beckett ; R.C. Green ; W. Jagust ; J.C. Morris ; O. Okonkwo ; R.J. Perrin ; R.C. Petersen ; M. Rivera Mindt ; A.J. Saykin ; L.M. Shaw ; A.W. Toga ; J.Q. Trojanowski ; and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2021): How Will Aducanumab Approval Impact AD Research?. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2021.46

OPEN ACCESS

Download PDF (135.8 Ko)View HTML